

Sheila J Thornton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1435382/publications.pdf>

Version: 2024-02-01

16
papers

631
citations

933447

10
h-index

996975

15
g-index

16
all docs

16
docs citations

16
times ranked

973
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery. <i>Nature Reviews Drug Discovery</i> , 2008, 7, 84-99.	46.4	209
2	Highly Effective Oral Amphotericin B Formulation against Murine Visceral Leishmaniasis. <i>Journal of Infectious Diseases</i> , 2009, 200, 357-360.	4.0	79
3	Enhancing drug absorption using lipids: A case study presenting the development and pharmacological evaluation of a novel lipid-based oral amphotericin B formulation for the treatment of systemic fungal infections. <i>Advanced Drug Delivery Reviews</i> , 2008, 60, 692-701.	13.7	69
4	A Novel Tropically Stable Oral Amphotericin B Formulation (iCo-010) Exhibits Efficacy against Visceral Leishmaniasis in a Murine Model. <i>PLoS Neglected Tropical Diseases</i> , 2010, 4, e913.	3.0	51
5	The Diving Response Mechanism and its Surprising Evolutionary Path in Seals and Sea Lions. <i>American Zoologist</i> , 1999, 39, 434-450.	0.7	47
6	The reformulation of Amphotericin B for oral administration to treat systemic fungal infections and visceral leishmaniasis. <i>Expert Opinion on Drug Delivery</i> , 2009, 6, 271-284.	5.0	41
7	Stroke volume and cardiac output in juvenile elephant seals during forced dives. <i>Journal of Experimental Biology</i> , 2005, 208, 3637-3643.	1.7	34
8	Barriers to treatment for visceral leishmaniasis in hyperendemic areas: India, Bangladesh, Nepal, Brazil and Sudan. <i>Drug Development and Industrial Pharmacy</i> , 2010, 36, 1312-1319.	2.0	22
9	Visceral leishmaniasis affects liver and spleen concentrations of amphotericin B following administration to mice. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 535-537.	3.0	20
10	Effect of dietary fat on hepatic liver X receptor expression in P-glycoprotein deficient mice: implications for cholesterol metabolism. <i>Lipids in Health and Disease</i> , 2008, 7, 21.	3.0	11
11	The Global Access Initiative at the University of British Columbia (UBC): Availability of UBC Discoveries and Technologies to the Developing World. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 791-794.	3.3	11
12	The effects of experimentally induced hyperthyroidism on the diving physiology of harbor seals (<i>Phoca vitulina</i>). <i>Frontiers in Physiology</i> , 2012, 3, 380.	2.8	11
13	Treatment with a Cholesterol Absorption Inhibitor (FM-VP4) Reduces Body Mass and Adipose Accumulation in Developing and Pre-Obese Mice. <i>Drug Development and Industrial Pharmacy</i> , 2007, 33, 1058-1069.	2.0	9
14	Evaluation of the Contribution of the ATP Binding Cassette Transporter, P-glycoprotein, to <i>in Vivo</i> Cholesterol Homeostasis. <i>Molecular Pharmaceutics</i> , 2013, 10, 3203-3212.	4.6	9
15	Dietary supplementation with phytosterol and ascorbic acid reduces body mass accumulation and alters food transit time in a diet-induced obesity mouse model. <i>Lipids in Health and Disease</i> , 2011, 10, 107.	3.0	8
16	Corrigendum to "Enhancing drug absorption using lipids: A case study presenting the development and pharmacological evaluation of a novel lipid-based oral amphotericin B formulation for the treatment of systemic fungal infections" [Advanced Drug Delivery Reviews 60 (2008) 692-701]. <i>Advanced Drug Delivery Reviews</i> , 2008, 60, 1675.	13.7	0